The ATS 2025 International Conference offers a robust scientific program highlighting cutting-edge advancements in pulmonary, critical care, and sleep medicine. This includes several Postgraduate Courses, Scientific Symposia, and Meet the Expert Sessions addressing new developments and considerations in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), as listed below. A curated list of clinical and scientific sessions related to these topics is also available on the ATS365 platform. For more information on these and other sessions to be presented May 16–21 in San Francisco, visit the online Advance Program.
- A1 CLINICAL YEAR IN REVIEW
- A11 CENTENNIAL CELEBRATION OF VA’S RESEARCH AND DEVELOPMENT PROGRAM
- A14 ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF ILD
- A16 BEYOND THE DUST: ADVANCING EXPOSURE ASSESSMENT, METABOLOMICS, AND TREATMENT IN OCCUPATIONAL LUNG DISEASES
- A18 BEST TRIALS IN PULMONARY REHABILITATION
- A22 BREAK ON THROUGH: AIRWAY EPITHELIAL BARRIER IN INFLAMMATION AND INJURY
- A23 MICROBIAL MAESTROS: ORCHESTRATION OF HOST-PATHOGEN INTERACTION
- A24 UPDATES IN RARE LUNG DISEASE, SARCOIDOSIS, AND LUNG TRANSPLANT
- A3 FELLOWS CASE CONFERENCE
- A30 BIOMARKERS, PREDICTORS, AND MODIFIERS OF PEDIATRIC PULMONARY OUTCOMES
- A33 BIOMARKER WINDOW INTO LUNG DISEASE
- A64 EVALUATION AND TESTING FOR PEDIATRIC LUNG DISEASES
- A66 CASE REPORTS IN CHILDHOOD INTERSTITIAL, DIFFUSE, AND RARE LUNG DISEASES
- A68 EXPANDING HORIZONS IN PULMONARY REHABILITATION: NOVEL APPLICATIONS, OUTCOMES, AND INNOVATIONS
- A73 CLINICAL REPORTS I: STRUCTURAL CURIOSITIES
- A8 EMPHYSEMA ACROSS DISEASES: FLAWED (RE)GENERATION OR RAPID DESTRUCTION?
- A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER CLINICIANS
- A87 VIRTUAL PULMONARY REHABILITATION: CAN WE GET TO CONSENSUS? A PRO/CON DEBATE
- A88 EPIGENETICS: HOW EARLY LIFE EXPOSURES CONTRIBUTE TO LUNG DISEASE LATER IN LIFE
- A93 BREATH OF HOPE: DECODING LUNG INJURY AND UNLOCKING TREATMENTS
- A95 NEW AND EXCITING BIOMARKERS IN ILD
- A99 ENDOTHELIAL DYNAMICS: INJURY, IMMUNITY AND THERAPEUTIC INNOVATIONS
- B1 CLINICAL YEAR IN REVIEW
- B101 FIXING BARRIERS: UNLOCKING TREATMENT MODALITIES IN INFLAMMATORY LUNG DISEASES
- B107 WHAT’S NEW IN PULMONARY REHABILITATION ASSESSMENT STRATEGIES?
- B108 INNOVATIVE INSIGHTS INTO LUNG INJURY: FROM INFLAMMATION TO BARRIER RESTORATION
- B11 BIOMARKERS IN PULMONARY FIBROSIS: GLEANING THROUGH AN OMICS LENS
- B15 MACROPHAGES: THE PAC-MAN OF THE IMMUNE SYSTEM
- B21 EQUITY, EFFECTIVENESS AND EXPERIENCE IN PR
- B23 DIFFUSE LUNG DISEASE AND PULMONARY HYPERTENSION: CLINICAL PERSPECTIVES
- B24 EPIDEMIOLOGICAL ADVANCES IN ILD
- B28 TRANSCRIPTIONAL AND MOLECULAR SIGNATURES IN PULMONARY FIBROSIS: PATHOGENESIS AND NOVEL INTERVENTIONS
- B29 AIRWAY AND ALVEOLAR EPITHELIAL RESPONSES: FROM INJURY MECHANISMS TO REGENERATIVE POTENTIAL
- B32 LUNG-GEVITY: IMMUNE MODULATION IN LUNG INJURY
- B34 BREATH-TAKING MECHANISMS IN COPD
- B35 ‘OMICS AND OUTCOMES: TRANSLATIONAL STUDIES ACROSS LUNG DISEASES
- B38 LUNG DISEASE IN ZEBRAS: RATE AND AUTOIMMUNE CASE REPORTS
- B59 SILENT ASSAULTS: LUNG DISEASE AND INFLAMMATION FROM DUST, FIRES, BLASTS, MILITARY DEPLOYMENT, AND THE WTC COLLAPSE
- B66 BRONCHOPULMONARY DYSPLASIA AND CONGENITAL CARDIORESPIRATORY DISEASES
- B74 ADVANCED MODELS AND MOLECULAR SIGNATURES FOR UNDERSTANDING AND TREATING PULMONARY FIBROSIS
- B75 TARGETING CELLULAR SENESCENCE, IMMUNE DYSREGULATION, AND METABOLISM IN LUNG INJURY AND FIBROSIS
- B76 CLINICAL REPORTS II: UNUSUAL SUSPECTS
- B83 PROGRESSIVE PULMONARY FIBROSIS: FIVE YEARS LATER
- B98 CELLULAR INTERACTIONS AND SIGNALING NETWORKS IN PULMONARY FIBROSIS
- C1 CLINICAL YEAR IN REVIEW
- C108 OPTIMIZING THE IMPACT OF PULMONARY REHABILITATION
- C109 IMMUNE AND CELLULAR MECHANISMS DRIVING AIRWAY DISEASES: FROM INFLAMMATION TO METABOLISM
- C11 MICROPLASTICS AND THEIR IMPACT ON HEALTH
- C15 ‘OMICS ODYSSEY ACROSS LUNG DISEASES
- C18 SPATIAL AND SINGLE-CELL ANALYSIS OF LUNG DISEASE: BRIDGING EARLY MECHANISMS TO THERAPEUTIC GAPS
- C27 GENETICS AND -OMICS TO PREDICT AND UNDERSTAND CHILDHOOD LUNG DISEASES
- C29 READING BETWEEN THE LINES IN INTERSTITIAL LUNG DISEASE
- C3 PEDIATRIC CLINICAL CHEST ROUNDS
- C55 EXPOSED: INJURY AND CANCER FROM VAPING, MARIJUANA, SMOKE, AND WORKPLACE HAZARDS
- C7 NEXT STEPS: ENHANCING RESEARCH TRIALS IN PULMONARY REHABILITATION TO IMPROVE REAL WORLD IMPLEMENTATION
- C73 ENVIRONMENTAL STRESSORS AND MOLECULAR MECHANISMS DRIVING LUNG INJURY AND DISEASE PATHOGENESIS
- C74 CELLULAR DYNAMICS, ECM REGULATION, AND INNOVATIVE MODELS IN LUNG PATHOBIOLOGY
- C81 ALPHABET SOUP! ILA, IPAF, PPF: AN INTERSTITIAL LUNG DISEASE PRO-CON
- C88 YES, A WHOLE SESSION ON MUCUS: LATEST RESEARCH INSIGHTS
- C89 FROM AIR TO AILMENTS: UNDERSTANDING THE IMPACT OF AIRBORNE POLLUTANTS AND PARTICULATE MATTER FROM DIFFERENT SOURCES ON HEALTH
- C9 MANY FACES OF ALVEOLAR TYPE II CELLS- PLASTICITY IN HEALTH AND DISEASE
- C93 ADVANCES IN INTERSTITIAL LUNG DISEASE AND PULMONARY HYPERTENSION: UNCOVERING NOVEL MECHANISMS, TARGETED THERAPIES, AND PERSONALIZED APPROACHES
- C99 THE ALVEOLAR NICHE AND EPITHELIAL REMODELING IN EARLY AND ADVANCED FIBROSIS
- D1 CLINICAL YEAR IN REVIEW
- D101 DISCOVERY OMICS AND COMPUTATIONAL STRATEGIES IN LUNG DISEASE RESEARCH
- D108 CELLULAR FATE, HOST-PATHOGEN INTERACTIONS, AND ENVIRONMENTAL INFLUENCES IN AIRWAY DISEASE
- D11 LONG-TERM CONSEQUENCES OF RESPIRATORY VIRAL INFECTIONS AND CHRONIC PULMONARY DISEASES: LONG-COVID, ASTHMA, ILD AND LUNG TRANSPLANT
- D17 MITOCHONDRIAL AND EPITHELIAL DYNAMICS IN CHRONIC AND ACUTE LUNG DISEASE
- D21 IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR
- D23 BEST CASE REPORTS IN CHRONIC LUNG DISEASE
- D24 CLINICAL CONUNDRUMS: CASE REPORTS
- D27 CELLULAR MECHANISMS AND IMMUNE PATHWAYS UNDERLYING PEDIATRIC PULMONARY DISEASES
- D29 FROM BENCH TO BEDSIDE: UNRAVELING PULMONARY FIBROSIS THROUGH CELLULAR COMMUNICATION AND MOLECULAR PATHWAYS
- D3 CHICKEN OR EGG: DISENTANGLING THE ROLE OF COMORBIDITIES IN FIBROTIC INTERSTITIAL LUNG DISEASES
- D30 GOING WITH THE FLOW: ABNORMALITIES IN RESPIRATORY MECHANICS
- D4 AI-DRIVEN INNOVATIONS IN PULMONARY AND CRITICAL CARE MEDICINE: A LOOK AHEAD
- D82 RESPIRATORY CONVERSATIONS: ADVANCES IN ORGAN-ORGAN CROSSTALK IN PULMONARY PATHOBIOLOGY
- D83 POST-INFECTIOUS PULMONARY COMPLICATIONS: TB, SARS-COV-2, AND BEYOND
- D85 RESPIRATORY MANIFESTATIONS OF ANCA-ASSOCIATED VASCULITIS: LESSONS FROM RECENTLY COMPLETED RCTS
- D97 IMMUNE-EPITHELIAL INTERACTIONS AND LUNG REPAIR IN INJURY AND REPAIR
- D98 TRACING THE SCAR IN INTERSTITIAL LUNG DISEASES
- MD1 RED JOURNAL IN ACTION 1: EARLY CAREER LUNG RESEARCH HIGHLIGHTS
- MD12 LUNGMAP PHASE 3- NOVEL TECHNOLOGY, DATA SCIENCE, AND RESOURCES
- MD16 RED JOURNAL IN ACTION 2: AIRWAYS MEET NEUROSCIENCE PERSPECTIVES
- MD19 ONE BREATH, MANY SPECIES: TRANSLATIONAL APPLICATIONS OF LUNG DISEASES
- MD2 STUDY UPDATES FROM THE AMERICAN LUNG ASSOCIATION’S AIRWAY CLINICAL RESEARCH CENTERS NETWORK
- MD20 THE TRANSPIRE STUDY- LUNG INJURY WITH PEDIATRIC HEMATOPOEITIC STEM CELL TRANSPLANTATION
- MD21 50 YEARS OF SUPPORTING LUNG RESEARCH: THE PARKER B. FRANCIS FELLOWSHIP
- MD22 EVALUATING INTERSTITIAL LUNG ABNORMALITIES AS EARLY RISK FACTORS FOR PULMONARY FIBROSIS
- MD28 HOW DO SHORT-LIVED LUNG INFECTIONS LEAD TO LONG-LASTING LUNG DAMAGE AND CHRONIC DISEASES?
- MD29 USE OF ARTIFICIAL INTELLIGENGE IN VHA’S LPOP IMPROVES SCREENING EFFICIENCY
- MD31 LUNGMAP PHASE 3- HIGH RESOLUTION MOLECULAR PROFILING OF LUNG DISEASES
- MD34 ARTIFICIAL INTELLIGENCE ON CHEST CT TO IMPROVE THE DEFINITION OF LUNG DISEASES AND THEIR SUBTYPES
- MD36 HIGHLIGHTS ON PRECLINICAL MODELS OF IPF – AN NHLBI CONSORTIUM
- MD5 NOVEL THERAPEUTIC TARGETS FOR PULMONARY ATERIAL HYPERTENSION (PAH)
- MTE1 CHOOSING AND MONITORING IMMUNOSUPPRESSION IN ILD PATIENTS
- MTE10 ANSWERING DIFFICULT CLINICAL QUESTIONS IN MANAGEMENT OF SARCOIDOSIS
- MTE13 ?HARD? DATA IN SCLERODERMA ILD: NEW GUIDELINES AND MANAGEMENT STRATEGIES
- MTE17 TWO BAD DISEASES ARE WORSE THAN ONE: PULMONARY HYPERTENSION IN ILD AND COPD
- MTE20 GENERATIVE AI FOR LUNG IMAGING AND DISEASE DIAGNOSIS
- MTE23 DON’T MISS IT: IDENTIFYING AND MANAGING EXPOSURES LINKED TO SARCOIDOSIS
- MTE29 ARTIFICIAL INTELLIGENCE AND THE FUTURE OF PULMONARY MEDICINE
- MTE34 FROM FEATHERS TO ANTIFIBROTICS: EXPOSURES, TREATMENT, AND PROGNOSIS IN HYPERSENSITIVITY PNEUMONITIS
- MTE36 MYOSITIS-ASSOCIATED ILD: UPDATES ON DIAGNOSTIC AND TREATMENT CHALLENGES
- NCE15 In the Spotlight: ILD Management for Women
- PG10 PULMONARY FUNCTION TESTING: STATE OF THE ART IN 2025
- PG14 UPDATES ON LUNG TRANSPLANTATION: WHAT PULMONOLOGISTS NEED TO KNOW
- PG15 INTEGRATIVE LUNG BIOINFORMATICS: FROM DATA TO DISCOVERY
- PG17 OCCUPATIONAL AND ENVIRONMENTAL LUNG DISEASE 101: DOES MY PATIENT HAVE OCCUPATIONAL LUNG DISEASE?
- PG2 BRONCH DAY 2025: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY, EBUS, AND GUIDED BRONCHOSCOPY
- PG5 PULMONARY HYPERTENSION: WHAT YOU NEED TO KNOW TODAY
- PG8 INNOVATIVE PRECLINICAL MODELS FOR HUMAN LUNG RESEARCH: BRIDGING THE GAP FROM BENCH TO BEDSIDE
- PG9 INTERSTITIAL LUNG DISEASE: IMPLEMENTING GUIDELINES FOR PATIENT CENTERED CARE
Register Today for ATS 2025
Register today for the ATS 2025 International Conference! Don’t miss the opportunity to experience this year’s premier respiratory health conference, May 16-21 in San Francisco. Join your colleagues to learn about the latest pulmonary, critical care, and sleep medicine developments. Not an ATS member? Join today and save on your conference registration!